Monte Rosa CMO sells 41,845 shares in plan trades
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported option exercises and share sales in GLUE stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported option exercises and share sales in GLUE stock. On June 23–24, he exercised options to acquire 36,000 shares of common stock at $7.56 per share and sold a total of 41,845 shares in open-market transactions at weighted average prices of $20.2214 and $21.4227 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026. After the transactions, he directly holds 59,992 shares of Monte Rosa common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
6 txns
Insider
Janku Filip
Role
Chief Medical Officer
Sold
41,845 shs ($882K)
Approx. gross sale proceeds
$882K
Approx. exercise cost
$272K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 30,000 | $7.56 | $227K |
| Sale | Common Stock | 30,000 | $21.4227 | $643K |
| Exercise | Stock Option (Right to Buy) | 6,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,000 | $7.56 | $45K |
| Sale | Common Stock | 11,845 | $20.2214 | $240K |
Holdings After Transaction:
Stock Option (Right to Buy) — 66,000 contracts (Direct);
Common Stock — 59,992 shares (Direct)
Footnotes (4)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The shares underlying this option are fully vested and exercisable.
Key Figures
Total shares sold: 41,845 shares
June 23 weighted average sale price: $20.2214 per share
June 24 weighted average sale price: $21.4227 per share
+3 more
6 metrics
Total shares sold
41,845 shares
Open-market sales on June 23–24, 2026
June 23 weighted average sale price
$20.2214 per share
Common stock sales on June 23, 2026
June 24 weighted average sale price
$21.4227 per share
Common stock sales on June 24, 2026
Options exercised
36,000 shares
Common stock acquired via option exercises
Option exercise price
$7.56 per share
Stock Option (Right to Buy) conversion
Post-transaction holdings
59,992 shares
Common stock directly held after June 24, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Monte Rosa Therapeutics (GLUE) report for Filip Janku?
Monte Rosa Therapeutics reported that Chief Medical Officer Filip Janku exercised options for 36,000 GLUE shares and sold 41,845 shares in open-market trades. The transactions occurred on June 23 and June 24, 2026, and were disclosed in a Form 4 filing.
Did the Monte Rosa (GLUE) CMO exercise stock options in this Form 4?
Yes. The Form 4 shows Filip Janku exercised stock options covering 36,000 Monte Rosa shares at an exercise price of $7.56 per share. These option exercises converted derivative positions into common stock immediately before related open-market sales on June 23 and June 24, 2026.
Were the GLUE insider sales made under a Rule 10b5-1 trading plan?
Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted by Filip Janku on March 4, 2026. Such pre-arranged plans allow insiders to schedule trades in advance, helping separate trading timing from day-to-day discretion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates